TY - JOUR
T1 - Cell-based tolerogenic therapy, experience from animal models of multiple sclerosis, type 1 diabetes and rheumatoid arthritis
AU - Stojanović, Ivana
AU - Dimitrijević, Mirjana
AU - Vives-Pi, Marta
AU - Mansilla, María José
AU - Pujol-Autonell, Irma
AU - Rodríguez-Fernandez, Silvia
AU - Palová-Jelínková, Lenka
AU - Funda, David P.
AU - Gruden-Movsesijan, Alisa
AU - Sofronić-Milosavljević, Ljiljana
AU - Hilkens, Catharien M.U.
AU - Martinez Caceres, Eva
AU - Miljković, Djordje
PY - 2017/1/1
Y1 - 2017/1/1
N2 - © 2017 Bentham Science Publishers. Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
AB - © 2017 Bentham Science Publishers. Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
KW - Cell-based tolerogenic therapy
KW - Multiple sclerosis
KW - Regulatory T cells
KW - Rheumatoid arthritis
KW - Tolerogenic dendritic cells
KW - Type 1 diabetes
U2 - 10.2174/1381612823666170214120708
DO - 10.2174/1381612823666170214120708
M3 - Review article
SN - 1381-6128
VL - 23
SP - 2623
EP - 2643
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 18
ER -
